105 related articles for article (PubMed ID: 8584609)
21. Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers.
van Marle S; van Vliet A; Sollie F; Kambayashi Y; Yamada-Sawada T
Int J Clin Pharmacol Ther; 2005 Jun; 43(6):282-93. PubMed ID: 15968885
[TBL] [Abstract][Full Text] [Related]
22. Safety and pharmacokinetics of ReN1869: a first human dose study in healthy subjects after single-dose administration.
Skrumsager BK; Ingwersen SH; Gerrits M
J Clin Pharmacol; 2003 Jan; 43(1):66-73. PubMed ID: 12520630
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects.
Shen Z; Gillen M; Miner JN; Bucci G; Wilson DM; Hall JW
Drug Des Devel Ther; 2017; 11():2077-2086. PubMed ID: 28744099
[TBL] [Abstract][Full Text] [Related]
24. Functional differentiation of multiple dopamine D1-like receptors by NNC 01-0012.
Sugamori KS; Hamadanizadeh SA; Scheideler MA; Hohlweg R; Vernier P; Niznik HB
J Neurochem; 1998 Oct; 71(4):1685-93. PubMed ID: 9751203
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
26. The effects of D1 (NNC 22-0215) and D2 (haloperidol) antagonists in a chronic double-blind placebo controlled trial in cebus monkeys.
Casey DE
Psychopharmacology (Berl); 1995 Oct; 121(3):289-93. PubMed ID: 8584608
[TBL] [Abstract][Full Text] [Related]
27. Chronic dopamine D1, dopamine D2 and combined dopamine D1 and D2 antagonist treatment in Cebus apella monkeys: antiamphetamine effects and extrapyramidal side effects.
Peacock L; Hansen L; Mørkeberg F; Gerlach J
Neuropsychopharmacology; 1999 Jan; 20(1):35-43. PubMed ID: 9885783
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers.
Hübner R; Högemann AM; Sunzel M; Riddell JG
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S19-25. PubMed ID: 9331000
[TBL] [Abstract][Full Text] [Related]
29. Randomized, crossover, single-blind, placebo-controlled, human pharmacology clinical trial with desoxypeganine, a new cholinesterase and selective MAO-A inhibitor: multiple-dose pharmacokinetics.
Algorta J; Pena MA; Alvarez A; Maraschiello C; Maruhn D; Windisch M; Mucke HA
Int J Clin Pharmacol Ther; 2009 Jul; 47(7):483-90. PubMed ID: 19640356
[TBL] [Abstract][Full Text] [Related]
30. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers.
Naik H; Vakilynejad M; Wu J; Viswanathan P; Dote N; Higuchi T; Leifke E
J Clin Pharmacol; 2012 Jul; 52(7):1007-16. PubMed ID: 21610201
[TBL] [Abstract][Full Text] [Related]
31. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety.
Purkins L; Wood N; Greenhalgh K; Allen MJ; Oliver SD
Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):10-6. PubMed ID: 14616408
[TBL] [Abstract][Full Text] [Related]
32. Incremental dosage of the new antipsychotic mazapertine induces tolerance to cardiovascular and cognitive effects in healthy men.
Kleinbloesem CH; Jaquet-Müller F; al-Hamdan Y; Baldauf C; Gisclon L; Wesnes K; Curtin CR; Stubbs RJ; Walker SA; Brunner-Ferber F
Clin Pharmacol Ther; 1996 Jun; 59(6):675-85. PubMed ID: 8681493
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics, Tolerability and Pharmacogenetics of DA-8031 After Multiple Ascending Doses in Healthy Male Subjects.
Hwang S; Lee DY; Cho JY; Chung JY; Jang IJ; Yu KS; Lee S
Drug Des Devel Ther; 2021; 15():2375-2384. PubMed ID: 34103898
[TBL] [Abstract][Full Text] [Related]
34. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
35. Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers.
Millar AW; Brown PD; Moore J; Galloway WA; Cornish AG; Lenehan TJ; Lynch KP
Br J Clin Pharmacol; 1998 Jan; 45(1):21-6. PubMed ID: 9489589
[TBL] [Abstract][Full Text] [Related]
36. Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjects.
Guérard N; Morand O; Dingemanse J
Orphanet J Rare Dis; 2017 Jan; 12(1):9. PubMed ID: 28088251
[TBL] [Abstract][Full Text] [Related]
37. Safety, tolerability, and pharmacokinetics of a single ascending dose of baicalein chewable tablets in healthy subjects.
Li M; Shi A; Pang H; Xue W; Li Y; Cao G; Yan B; Dong F; Li K; Xiao W; He G; Du G; Hu X
J Ethnopharmacol; 2014 Oct; 156():210-5. PubMed ID: 25219601
[TBL] [Abstract][Full Text] [Related]
38. Multiple-dose pharmacokinetics, pharmacodynamics and tolerability of the oral ET(A) endothelin-receptor antagonist SPP301 in man.
Dieterle W; Mann J; Kutz K
Int J Clin Pharmacol Ther; 2005 Apr; 43(4):178-86. PubMed ID: 15966464
[TBL] [Abstract][Full Text] [Related]
39. Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers.
Martin DE; Blum R; Doto J; Galbraith H; Ballow C
Clin Pharmacokinet; 2007; 46(7):589-98. PubMed ID: 17596104
[TBL] [Abstract][Full Text] [Related]
40. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
